A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial Of Deferasirox In Patients With Myelodysplastic Syndromes (Low/Int-1 Risk) And Transfusional Iron Overload (Telesto).
Phase of Trial: Phase III
Latest Information Update: 08 Jun 2016
At a glance
- Drugs Deferasirox (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- Acronyms Telesto
- Sponsors Novartis Pharmaceuticals
- 30 Jun 2012 New source identified and integrated (9L11-2: University of Southern California Norris Comprehensive Cancer Center).
- 30 Jun 2012 Additional lead trial investigator identified as reported by University of Southern California Norris Comprehensive Cancer Center.
- 22 Jun 2010 New trial record